An observational study in Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Monoclonal Gammopathy of Undetermined Significance · United States.
Among the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, this one is the 12th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2015, is one of 20 observational ones, reaches primary completion later than 9 of the 17 other live ones, and was the 54th registered.
102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.
Browse Monoclonal Gammopathy of Undetermined Significance studies →15 of the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 30+ · Healthy volunteers
Regeneron Pharmaceuticals · Sites in United States, Belgium, France and 4 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Monoclonal Gammopathy of Undetermined Significance studies recruiting now, 18 (90%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 21 · Phase 3 9
First in 1992; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 388 across 34 observational studies indexed under Monoclonal Gammopathy of Undetermined Significance.
Median enrollment 40 across the 43 interventional studies, 217 across the 20 observational. Of the 52 that completed or were terminated, 15 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 76 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 3 studies filed under Monoclonal Gammopathy of Undetermined Significance — fewer than ten, so there is no comparison to draw.
4 of the studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05640843Memorial Sloan Kettering Cancer CenterA Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | 2026-11 |
| NCT05136807M.D. Anderson Cancer CenterQuality of Life in Patients With Asymptomatic Monoclonal Gammopathies | 2027-02-02 |
| NCT05361694University of MiamiTwo Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions | 2027-07-01 |
| NCT06055894Memorial Sloan Kettering Cancer CenterA Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
PRIMARY OBJECTIVE:
I. To determine the rate of progression to multiple myeloma after 3 years of follow up.
SECONDARY OBJECTIVES:
I. To describe baseline patient characteristics and clinical variables. II. To identify molecular and genetic correlates that may predict for progression to multiple myeloma (MM).
OUTLINE:
Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, positron emission tomography (PET)/computed tomography (CT) scans, and/or magnetic resonance imaging (MRI) scans to check the status of disease at the discretion of the treating physician.
After completion of 3 years on study, patients are followed up every 6-12 months thereafter.
Patients with monoclonal gammopathy of unknown significance and/or smoldering multiple myeloma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with monoclonal gammopathy of unknown significance. Both criteria must be met:
Patients with smoldering multiple myeloma. Both criteria must be met:
Exclusion Criteria:
Evidence of myeloma defining events or biomarkers of due to underlying plasma cell proliferative disorder meeting at least one of the following
Prior or concurrent systemic treatment for asymptomatic monoclonal gammopathies
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
Procedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis
Undergo collection of blood samples
Correlative studies
Rate of progression to multiple myeloma (MM)
Kaplan-Meier method will be used to estimate time to MM progression. Log-rank test will be used to evaluate the difference in rate of progression between/among patient groups.
Time frame: 3 years
Progression free survival
Will be estimated using the Kaplan-Meier method. Log-rank test will be used to evaluate the difference in rate of progression free survival between/among patient groups.
Time frame: 3 years
Overall survival
Will be estimated using the Kaplan-Meier method. Log-rank test will be used to evaluate the difference in rate of overall survival between/among patient groups.
Time frame: 3 years
Baseline patient characteristics and clinical variables
Summary statistics including mean, standard deviation, median, and range will be provided for continuous variables. Frequency counts and percentages will be used to summarize categorical variables.
Time frame: Baseline
Molecular and genetic profile analysis
Will study the correlation of molecular and genetic profiles with time to MM progression.
Time frame: 3 years
Molecular profiling analysis of patients who develop MM
Analysis will include whole exome sequencing and gene expression profiling and cellular (including flow cytometry) profiling using bone marrow and peripheral blood samples.
Time frame: 3 years
Immune characterization of patients who develop MM
Analysis will include cell surface and functional studies of dendritic, T-, B-, natural killer (NK)- and NKT-cells using peripheral blood samples.
Time frame: 3 years
Immune characterization of patients who develop MM
Analysis will include cell surface and functional studies of dendritic, T-, B-, NK- and NKT-cells using bone marrow samples.
Time frame: 3 years
Started Dec 2015 (actual). Primary completion is estimated for Apr 2028, 148 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Monoclonal Gammopathy of Undetermined Significance →